Mylan Pharma

The transaction in India will be closed upon receipt of regulatory approvals, Pfizer Ltd said

The company has also launched a 24x7 helpline using which patients and healthcare practitioners can access information about the drug and its availability

Mylan's version comes after two Indian drugmakers, Cipla Ltd and privately-held Hetero Labs Ltd, launched their generic versions of the drug

Biocon Biologics, through its partner Mylan, has commercialised three of its co-developed biosimilars in developed markets like the US, Canada, the European Union and Australia.

Mylan is notifying its distributors and customers by letter and is arranging for return of all recalled products

Sanofi is heavily reliant on Lantus and Mylan's own insulin drug would be its second competitor after Eli Lilly launched its version in late 2016

BS ReporterHyderabad, 27 July: Mylan Pharmaceuticals Private Limited, a subsidiary of Mylan N V, today announced the launch of Velpatasvir 100 mg/Sofosbuvir 400 mg tablets under the brand name MyHep All in India. MyHep All is a fixed-dose combination tablet indicated for the treatment of chronic hepatitis C virus infection in adults, including all six major HCV genotypes. A Velpatasvir 100 mg /Sofosbuvir 400 mg combination product is currently sold by Gilead Sciences in other markets under the brand name EPCLUSA, according to the company. HCV is a bloodborne virus commonly transmitted through unsafe injection practices, inadequate sterilization of medical equipment, and the transfusion of unscreened blood and blood products. HCV also can be transmitted sexually and can be passed from an infected mother to her baby. "Chronic hepatitis C is a significant public health burden in India. When we launched Mylan's Hepato Care division in January 2015, we did so to increase access to ...